Cancer Letters
Volume 230, Issue 2 , Pages 292-294 , 18 December 2005

Comments on ‘Cytogenetic effects in children treated with methylphenidate’ by El-Zein et al.

  • R. Julian Preston

      Affiliations

    • Environmental Carcinogenesis Division, NHEERL, U.S. Environmental Protection Agency, Research Triangle Park, NC 27711, USA
    • Corresponding Author InformationCorresponding author. Tel. +1 919 541 0276
    • ,
  • Scott H. Kollins

      Affiliations

    • Duke ADHD Program, Department of Psychiatry, Duke University Medical Center, 718 Rutherford Street, Durham, NC 27705, USA
    • ,
  • James M. Swanson

      Affiliations

    • Department of Pediatrics, University of California, Irvine19722, MacArthur Blvd., Irvine, CA 92612, USA
    • ,
  • Laurence L. Greenhill

      Affiliations

    • Research Unit of Pediatric Psychopharmacology Psychosocial Intervention, New York State Psychiatric Institute, 1061 Riverside Drive, New York, NY 10032, USA
    • ,
  • Tim Wigal

      Affiliations

    • Department of Pediatrics, University of California, Irvine19722, MacArthur Blvd., Irvine, CA 92612, USA
    • ,
  • Glen R. Elliott

      Affiliations

    • The Children's Center at Langley Porter, Department of Psychiatry, University of California, San Francisco, 401 Parnassus Avenue, Box 0984F, San Francisco, CA 94143-0984, USA
    • ,
  • Benedetto Vitiello

      Affiliations

    • National Institute of Mental Health, 6001 Executive Blvd Room 7147, Bethesda, MD 20892-9633, USA

Received 16 May 2005 ,Accepted 22 May 2005.

References 

  1. El-Zein RA, Abdel-Rahman SZ, Hay MJ, Lopez MS, Bondy ML, Morris DL, et al. Cytogenetic effects in children treated with methylphenidate. Cancer Letters. 2005;1–8
  2. NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Methylphenidate, March 2005, Available at http://cerhr.niehs.nih.gov/news/stimulants/reports.html.
  3. NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine, March 2005, Available at http://cerhr.niehs.nih.gov/news/stimulants/reports.html.
  4. Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Research. 1989;49:5736–5747
  5. Dunnick JK, Hailey JR. Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology. 1995;103:77–84
  6. NTP, Toxicology and carcinogenesis studies of methylphenidate hydrochloride (CAS no. 298-59-9) in F344/N rats and B6C3F1 mice (feed studies), Research Triangle Park, NC: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Toxicology Program; 1995.
  7. Physician drug and diagnosis audit 2003, Newton Mass, Scott-Levin Associates, 2003.
  8. Robison LM, Selar DA, Skaer TL, Galin RS. Treatment modalities among US children diagnosed with attention-deficit hyperactivity disorder: 1995-1999. International Clinical Psychopharmacology. 2004;19:17–22
  9. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. Journal of American Medical Association. 2000;283:1025–1030

PII: S0304-3835(05)00537-9

doi: 10.1016/j.canlet.2005.05.038

Cancer Letters
Volume 230, Issue 2 , Pages 292-294 , 18 December 2005

Article Tools